Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
321.81
Nov 16 • 4:20 AM ET Dollar change+0.90 Percentage change(0.28%)
Index
RUI
Market Cap
12.68B
Enterprise Value
12.22B
Income
157.02M
Sales
1.56B
Book/sh
40.18
Cash/sh
17.09
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
0.00%
Employees
4700
IPO
Sep 18, 2015
P/E
81.01
Forward P/E
53.52
PEG
2.41
P/S
8.13
P/B
8.01
P/C
18.83
P/FCF
63.33
EV/EBITDA
58.37
EV/Sales
7.83
Quick Ratio
3.92
Current Ratio
5.89
Debt/Eq
0.13
LT Debt/Eq
0.12
Option/Short
Yes / Yes
EPS (ttm)
3.97
EPS next Y
6.01
EPS next Q
1.44
EPS this Y
23.89%
EPS next Y
26.39%
EPS next 5Y
22.24%
EPS past 3/5Y
- -
Sales past 3/5Y
18.33% 20.16%
EPS Y/Y TTM
-5.62%
Sales Y/Y TTM
16.98%
EPS Q/Q
-8.53%
Sales Q/Q
15.64%
Insider Own
2.87%
Insider Trans
0.00%
Inst Own
89.56%
Inst Trans
11.60%
ROA
8.33%
ROE
10.67%
ROIC
8.84%
Gross Margin
66.71%
Oper. Margin
12.13%
Profit Margin
10.06%
SMA20
-0.03%
SMA50
0.52%
SMA200
-1.14%
Trades
Shs Outstand
39.41M
Shs Float
38.28M
52W High
362.41 -11.20%
52W Low
274.55 17.21%
Volatility
0.70% 0.78%
ATR (14)
2.45
RSI (14)
51.89
Beta
0.69
Rel Volume
0.12
Avg Volume
353.56K
Volume
2,108
Perf Week
-0.01%
Perf Month
0.30%
Perf Quarter
-0.91%
Perf Half Y
-1.45%
Perf YTD
3.51%
Perf Year
14.90%
Perf 3Y
43.88%
Perf 5Y
21.25%
Perf 10Y
393.95%
Prev Close
320.91
Price
321.81
Change %
0.28%
Consensus
Hold
Avg. Price Target
$364.25
Implied Upside
+13.2%
Analysts14incl. previous ratings
Rating Distribution12 Buy · 1 Hold · 1 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Dec 18, 2025Upgrade
JPM logoJJP Morgan
Neutral → Overweight$370+15.0%
Dec 11, 2025Upgrade
C logoCCitigroup
Neutral → Buy$350+8.8%
Nov 18, 2025Initiated
WFC logoWWells Fargo
Underweight$15-95.3%
Oct 08, 2025Upgrade
NNeedham
Hold → Buy$326+1.3%
Sep 02, 2025Initiated
EVR logoEEvercore ISI
Outperform$300-6.8%
Mar 14, 2025Initiated
BAC logoBBofA Securities
Buy$320-0.6%
Jan 21, 2025Initiated
UBS logoUUBS
Buy$305-5.2%
Dec 17, 2024Initiated
OPY logoOOppenheimer
Outperform$275-14.5%
Dec 11, 2024Upgrade
WFC logoWWells Fargo
Equal Weight → Overweight$190 → $275-14.5%
Sep 18, 2024Initiated
SF logoSStifel
Buy$238-26.0%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Grewal HarpreetDirectorApr 02 '26Sale328.2210032,8228,719Apr 06 08:02 PM
Grewal HarpreetDirectorApr 02 '26Proposed Sale328.2210032,822Apr 02 03:59 PM
Yuen MaggieChief Financial OfficerMar 02 '26Sale342.302,432832,47418,353Mar 04 07:31 PM
MAGGIE YUENOfficerMar 02 '26Proposed Sale342.302,432832,474Mar 02 04:11 PM
Grewal HarpreetDirectorJan 06 '26Sale312.6418658,1518,230Jan 08 09:06 PM
Wilder ThomasDirectorJan 02 '26Sale310.7218657,7940Jan 06 07:33 PM
Grewal HarpreetDirectorJan 06 '26Proposed Sale312.6418658,151Jan 06 03:52 PM
THOMAS WILDERDirectorJan 02 '26Proposed Sale310.7218657,794Jan 02 04:02 PM
Bose AraniDirectorDec 11 '25Sale308.8215,0004,632,292258,462Dec 15 07:30 PM
Roberts JohannaEVP, Gen. Counsel & SecretaryDec 05 '25Sale300.1330090,03963,836Dec 09 08:01 PM
Roberts JohannaEVP, Gen. Counsel & SecretaryDec 01 '25Sale294.94600176,96664,136Dec 03 07:45 PM
Grewal HarpreetDirectorDec 02 '25Sale292.9810029,2988,416Dec 03 07:44 PM
Grewal HarpreetDirectorDec 02 '25Proposed Sale292.9810029,298Dec 02 03:59 PM
Roberts JohannaEVP, Gen. Counsel & SecretaryNov 25 '25Sale300.061,800540,10864,736Nov 26 07:36 PM
Bose AraniDirectorNov 25 '25Sale300.197,5002,251,425275,261Nov 26 07:36 PM
Bose AraniDirectorNov 21 '25Sale290.567,5002,179,212282,761Nov 25 07:59 PM
Johanna RobertsOfficerNov 25 '25Proposed Sale298.112,100626,031Nov 25 05:20 PM
Arani BoseAffiliateNov 21 '25Proposed Sale279.7930,0008,393,700Nov 21 05:21 PM
Penumbra, Inc. is a thrombectomy company, which designs, develops, manufactures, and markets innovative medical products. It offers neurovascular thrombectomy and embolization and access technologies, neurosurgical tools, Penumbra LANTERN Delivery Microcatheter, and Penumbra Occlusion Device system. The company was founded by Arani Bose and Adam Elsesser on June 21, 2004 and is headquartered in Alameda, CA.
Co-FounderMr. Adam Elsesser J.D.
PresidentMs. Shruthi Narayan
Co-Founder & DirectorDr. Arani Bose M.D.
Chief Financial OfficerMs. Maggie S. Yuen
Chief Accounting OfficerMr. Lambert Shiu